In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents

LY303366 is a new semisynthetic echinocandin derivative with potent, broad-spectrum fungicidal activity. We investigated the in vitro activity of LY303366, amphotericin B, flucytosine (5FC), fluconazole, and itraconazole against 435 clinical yeast isolates (413 Candida and 22 Saccharomyces cerevisiae isolates) obtained from over 30 different medical centers. MICs for all five antifungal agents were determined by the National Committee for Clinical Laboratory Standards method with RPMI 1640 test medium. LY303366 was also tested in antibiotic medium 3 as specified by the manufacturer. Overall, LY303366 was quite active against all of the yeast isolates when tested in RPMI 1640 (MIC at which 90% of the isolates are inhibited [MIC90], 1.0 microg/ml) but appeared to be considerably more potent when tested in antibiotic medium 3 (MIC90, 0.03 microg/ml). When tested in antibiotic medium 3, LY303366 was 16- to >2,000-fold more active than itraconazole, fluconazole, amphotericin B, or 5FC against all species except Candida parapsilosis. When tested in RPMI 1640, LY303366 was comparable to amphotericin B and itraconazole and more active than fluconazole and 5FC. All of the isolates for which fluconazole and itraconazole had elevated MICs (> or = 128 and > or = 2.0 microg/ml, respectively) were inhibited by < or = 0.007 microg of LY303366/ml when tested in antibiotic medium 3 and < or = 0.5 microg/ml when tested in RPMI 1640. Based on these studies, LY303366 has promising antifungal activity and warrants further in vitro and in vivo investigation.

• Publication year

  1997

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1997-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.41.4.763PMID 9087485PMCID PMC163790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole

  1996cited by this paper
• Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine

  1995cited by this paper
• Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019.

  1988cited by this paper
• In vitro and in vivo anti-Candida activity and toxicology of LY121019.

  1984cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Manual of clinical microbiology

  1975cited by this paper

• Structure–activity relationships of bensulfuron methyl and its derivatives as novel agents against drug‐resistant Candida auris

  2023cites this paper
• Antimicrobial and cytotoxic activity of green synthesis silver nanoparticles targeting skin and soft tissue infectious agents

  2021cites this paper
• Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

  2014cites this paper
• Anidulafungin

  2012cites this paper
• Resistance to Antifungal Drugs

  2011cites this paper
• The Cell Wall of Cryptococcus

  2011cites this paper
• Rare and emerging Candida species

  2009cites this paper
• Pharmacology and Antifungal Properties of Anidulafungin, a New Echinocandin

  2009cites this paper
• Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility

  2009cites this paper
• CHAPTER 24 – Cutaneous and subcutaneous mycoses

  2009cites this paper
• [Anidulafungin].

  2008cites this paper
• [Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin].

  2008cites this paper
• Nueva aportación en terapia antifúngica: Anidulafungina. Aspectos farmacológicos de la anidulafungina

  2008cites this paper
• Anidulafungine : activité in vitro sur les levures et les champignons filamenteux d’intérêt clinique

  2007cites this paper
• In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.

  2006cites this paper
• The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications

  2006cites this paper
• Echinocandin antifungals: review and update

  2006cites this paper
• Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

  2006cites this paper
• Developments in the treatment of candidiasis: more choices and new challenges

  2006cites this paper
• Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis

  2005cites this paper
• Antifungal Targets and Research into Antifungal Agents

  2005cites this paper
• In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

  2005cites this paper
• Advances and challenges in management of invasive mycoses.

  2005cites this paper
• Anidulafungin: a new echinocandin with a novel profile.

  2005cites this paper
• Anidulafungin: A Potent Antifungal that Targets Candida and Aspergillus

  2005cites this paper
• Invasive Saccharomyces infection: a comprehensive review.

  2005influential citation
• Coccidioides posadasii Contains a Single 1,3-β-Glucan Synthase Gene That Appears To Be Essential for Growth

  2005cites this paper
• In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates

  2004cites this paper
• Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases. May 1-4, 2004. Prague, Czech Republic.

  2004cites this paper
• Anidulafungin: an echinocandin antifungal

  2004cites this paper
• Antifungal Agents: In Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy

  2004cites this paper
• A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

  2004cites this paper
• Therapy of common superficial fungal infections

  2004cites this paper
• In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

  2003cites this paper
• Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

  2003cites this paper
• In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

  2003cites this paper
• Anidulafungin Vicuron.

  2003cites this paper
• In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

  2003cites this paper
• Adding 2% glucose to culture media does not influence the activity of caspofungin against Candida species.

  2003cites this paper
• Activitat in vitro de nous antifúngics i epidemiologia molecular de les infeccions per "Candida albicans"

  2002cites this paper
• Deeply invasive candidiasis.

  2002cites this paper
• New agents for the treatment of systemic fungal infections – current status

  2002cites this paper
• Clinical relevance of mechanisms of antifungal drug resistance in yeasts.

  2002cites this paper
• Investigational Antifungal Agents

  2001cites this paper
• Glucan synthase inhibitors as antifungal agents.

  2001cites this paper
• Clinical efficacy of echinocandin antifungals

  2001cites this paper
• Antifungal Pharmacodynamics: Concentration‐Effect Relationships in Vitro and in Vivo

  2001cites this paper
• Les nouveaux antifongiques et leur straégie de recherche

  2001cites this paper
• In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus andFusarium Isolates

  2001cites this paper
• Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

  2001cites this paper
• THE ECHINOCANDINS, FIRST NOVEL CLASS OF ANTIFUNGALS IN TWO DECADES: WILL THEY LIVE UP TO THEIR PROMISE?

  2001cites this paper
• In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.

  2001cites this paper
• Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts.

  2001cites this paper
• New agents for treatment of systemic fungal infections

  2000cites this paper
• Efficacy of FK463, a (1,3)-β-d-Glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida albicans Infection in Mice

  2000cites this paper
• Antifungal Pharmacodynamics: Review of the Literature and Clinical Applications

  2000cites this paper
• New targets and delivery systems for antifungal therapy.

  2000cites this paper
• New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

  2000cites this paper
• In Vitro Activity of A-192411.29, a Novel Antifungal Lipopeptide

  2000influential citation
• Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

  2000cites this paper
• Antifongiques

  1999cites this paper
• LY303366 Exhibits Rapid and Potent Fungicidal Activity in Flow Cytometric Assays of Yeast Viability

  1999cites this paper
• Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens

  1999cites this paper
• Design and preparation of cyclopeptamine antifungal agents.

  1999cites this paper
• [The future of antifungal agents. Non azole antifungal agents].

  1999cites this paper
• [Review article. Molecular basis of antimycotic therapy].

  1999cites this paper
• Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development.

  1999cites this paper
• New developments in antifungals.

  1999cites this paper
• Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits

  1999cites this paper
• A Glucan Synthase FKS1 Homolog inCryptococcus neoformans Is Single Copy and Encodes an Essential Function

  1999cites this paper
• übersichtsartikel Molekulare Grundlagen der antimykotischen Therapie: Review Article: Molecular basis of antimycotic therapy

  1999cites this paper
• Systemic Antifungal Agents

  1999cites this paper
• New developments in antifungals

  1999cites this paper
• In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.

  1998cites this paper
• Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents

  1998influential citation
• Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cites this paper
• Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

  1998cites this paper
• Compounds against Emerging Pathogens Antifungal Peptides : Novel Therapeutic

  1998cites this paper
• Importance of antifungal drug-resistance: clinical significance and need for novel therapy.

  1998cites this paper
• Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis

  1998cites this paper
• Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

  1998cites this paper
• Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

  1998cites this paper
• Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods

  1998cites this paper
• Chapter 17 – Non-Azole Antifungal Agents

  1998cites this paper
• In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against Aspergillus spp

  1998cites this paper
• Photoaffinity Analog of the Semisynthetic Echinocandin LY303366: Identification of Echinocandin Targets inCandida albicans

  1998cites this paper
• Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366

  1998cites this paper
• Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

  1997cites this paper
• Update on antifungal resistance.

  1997cites this paper
• Galgiani species and Cryptococcus neoformans . MK-0991 , and fluconazole against Candida echinocandin LY 303366 , the pneumocandin Comparison of the in vitro activities of the

  1997cites this paper